Transcriptional Suppression of miR-7 by MTA2 Induces Sp1-Mediated KLK10 Expression and Metastasis of Cervical Cancer.
KLK10
MTA2
Sp1
cervical cancer
miRNA-7
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
05 Jun 2020
05 Jun 2020
Historique:
received:
01
03
2020
revised:
18
04
2020
accepted:
22
04
2020
pubmed:
14
5
2020
medline:
14
5
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
MTA2 is involved in tumor proliferation and metastasis. However, the role of MTA2 in cervical cancer thus far has not been identified. In this study, we report that elevated expression of MTA2 negatively correlates with Kallikrein-10 (KLK10) expression and poor prognosis of cervical cancer patients. Knockdown of MTA2 substantially inhibited tumor cell migration and invasion, and it enhanced KLK10 expression of the cervical cancer cells in vitro and in vivo. Functionally, shMTA2-mediated suppression of cell mobility was significantly restored by knockdown of KLK10. We also found that Sp1 (transcription factor specificity protein 1) is critical for shMTA2-induced transcriptional upregulation of KLK10 and subsequent biological functions. Furthermore, we found that the expression of miR-7 is elevated by MTA2 silencing and then by direct inhibition of Sp1 expression. Knockdown of Sp1 additively enhanced KLK10 expression in MTA2-knocked down cervical cancer cells, suggesting that the miR-7/Sp1 axis acts as an effector of MTA2 to impact KLK10 levels and mobility of cervical cancer cells. Taken together, our findings provide new insights into the physiological relationship between MTA2 and KLK10 via regulating the miR-7/Sp1 axis, and they provide a potential therapeutic target in cervical cancer.
Identifiants
pubmed: 32402941
pii: S2162-2531(20)30117-7
doi: 10.1016/j.omtn.2020.04.009
pmc: PMC7218230
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
699-710Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
FEBS Lett. 2013 Jul 11;587(14):2247-53
pubmed: 23742934
J Cell Physiol. 2019 Dec;234(12):22195-22206
pubmed: 31102265
Exp Mol Med. 2018 Jan 19;50(1):e429
pubmed: 29350680
Cancer Res. 2012 Jan 15;72(2):387-94
pubmed: 22253283
Cancer Sci. 2010 Apr;101(4):934-40
pubmed: 20180809
Genes Chromosomes Cancer. 2009 Dec;48(12):1057-68
pubmed: 19760608
Gene. 2012 Jul 25;503(2):200-7
pubmed: 22564704
Biochim Biophys Acta. 2014 Apr;1845(2):255-65
pubmed: 24569228
Crit Rev Oncol Hematol. 2019 May;137:9-17
pubmed: 31014518
Int J Oncol. 2016 Oct;49(4):1531-1540
pubmed: 27633373
Ann Oncol. 2009 Jun;20(6):1020-5
pubmed: 19150938
Med Sci Monit. 2018 Sep 16;24:6506-6516
pubmed: 30219819
Int J Clin Exp Pathol. 2015 Jun 01;8(6):7173-80
pubmed: 26261611
Clin Biochem. 2013 Oct;46(15):1453-61
pubmed: 23499583
Cancer Metastasis Rev. 2014 Dec;33(4):921-8
pubmed: 25394532
Cancer Res. 2003 Feb 15;63(4):807-11
pubmed: 12591730
Jpn J Clin Oncol. 2015 Aug;45(8):755-66
pubmed: 25969565
EMBO J. 2012 Jan 4;31(1):110-23
pubmed: 21983900
Target Oncol. 2012 Jun;7(2):135-43
pubmed: 22585429
Cancer Sci. 2010 Jun;101(6):1463-70
pubmed: 20384626
Sci Rep. 2015 Nov 30;5:17426
pubmed: 26616394
J Cell Physiol. 2019 Aug;234(8):13332-13341
pubmed: 30604866
Breast Cancer Res Treat. 2013 Sep 28;141(3):375-384
pubmed: 24077732
Cancer Res. 2001 Nov 1;61(21):8014-21
pubmed: 11691827
Oncol Rep. 2015 Nov;34(5):2325-32
pubmed: 26479703
Mini Rev Med Chem. 2019;19(20):1707-1716
pubmed: 31483230
Int J Mol Sci. 2017 Dec 21;19(1):
pubmed: 29267213
Oncol Rep. 2016 Sep;36(3):1569-75
pubmed: 27431648
Int J Clin Exp Med. 2015 Jan 15;8(1):480-7
pubmed: 25785020
Cell Physiol Biochem. 2018;46(1):322-334
pubmed: 29590661
Biochim Biophys Acta Mol Cell Res. 2017 Oct;1864(10):1867-1876
pubmed: 28760656
J Invest Dermatol. 2011 Nov;131(11):2213-22
pubmed: 21753780
Adv Clin Chem. 2005;39:11-79
pubmed: 16013667